United States-based drugmaker Eli Lilly on 21 November 2025, grew to become the primary pharmaceutical firm and solely the second non-technology agency, to enter the trillion-dollar market capitalisation membership after its inventory value rose 1.7%.
Within the early US inventory market session, shares of the pharma big jumped 1.7% to hit an intraday excessive of $1,061.17, in comparison with $1,043.29 on the earlier market shut, in keeping with MarketWatch knowledge.
“At a trillion, it’s two instances as huge because the second largest firm in well being care. That’s an unimaginable scenario for them,” Jared Holz, a strategist at Mizuho Securities USA LLC instructed Bloomberg.
Why did Eli Lilly’s inventory achieve?
The soar got here as Wall Avenue pundits and buyers wager huge on the drugmaker’s GLP-1s medicines, used to deal with weight problems and diabetes, together with its subsequent technology weight-loss capsule out there projected to succeed in $95 billion by 2030, as per a Bloomberg report.
After its shares fell in Could as a result of excessive tariffs (imposed by US President Donald Trump), and setbacks to its weight-loss drug Zepbound (drug profit supervisor CVS Well being Corp. dropped Zepbound from its checklist of most well-liked medication and changed it with Novo Nordisk A/S’s Wegovy), since September, the inventory has gained.
Its better-than-expected Q3 earnings, raised outlook and a take care of the Trump administration, helped propel it to new heights, the report added. In 2025, Eli Lilly shared have risen 37% thus far, after a 32% rally in 2024.
Why are the buyers betting on Eli Lilly?
Traders are doubling down on the drugmaker to keep up its pole place within the weight-loss medication market. Knowledge thus far has proven the maker beat its Danish competitor Novo Nordisk in weight problems drug efficiency.
A one-on-one comparability between Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy in Could 2025 confirmed that the previous’s experimental capsule helped sufferers shed weight and management blood sugar about in addition to Ozempic in a separate trial. And whereas Zepbound gross sales have topped Wall Avenue’s expectations thus far this yr, Novo has needed to trim its annual forecast 4 instances amid lagging gross sales.
In its most up-to-date quarterly outcomes, the US drugmaker mentioned that its GLP-1 medication now account for nearly 58% of that market, which incorporates Novo’s Ozempic and Wegovy.
“While you take a look at what they’ve performed facet by facet in opposition to Novo, which had the early lead in weight problems, to return in and take principally two thirds of latest market share inside two years is form of unimaginable. By way of their execution, it’s been constantly good,” Holz added.
Now, Wall Avenue is popping its consideration to the area’s subsequent part — an easy-to-swallow capsule that’s inexpensive to make.
A US Meals and Drug Administration (US FDA) resolution on whether or not to approve Lilly’s oral weight problems remedy is anticipated in early 2026 and the agency has bulked up provide forward of a possible launch. Citi’s Geoff Meacham, who estimates annual gross sales for the capsule will peak at greater than $40 billion, assigned Lilly a $1,500 value goal final week — the very best on Wall Avenue.
“Lilly’s domination of the class ought to speed up,” Meacham wrote. His value goal suggests the corporate’s market worth would high $1.4 trillion over the following 12 months.
In the meantime, a slew of builders are racing to copy the drugmaker’s success. To remain within the lead, Lilly is operating research of tirzepatide — the chemical compound in Zepbound — in associated well being situations like liver illness, coronary heart failure and immunological illnesses. The corporate can be inspecting its experimental weight problems capsule, orforglipron, in hypertension and sleep apnea.
Mizuho’s Holz sees additional upside for Lilly shares if the corporate continues to seek out development drivers, whether or not in its weight problems franchise or its Alzheimer’s program.
“Is it doable that in three, 4, 5 years, it is a $2 trillion firm? Positive, very doable.” Holz mentioned.
(With inputs from Bloomberg)
